CDH11 and breast carcinoma: Celecoxib and DMC inhibit the growth of CDH11 positive MDA-MB-231, BT549 and Hs578T basal-like breast cancer cells with EC50s in the 1-5 micromolar range but did not affect CDH11 negative MCF7 cells up to 40 micromolar (Figure 4E, F, Supplementary Fig. S4A, B).